Literature DB >> 9660747

Lineage-specific signaling in melanocytes. C-kit stimulation recruits p300/CBP to microphthalmia.

E R Price1, H F Ding, T Badalian, S Bhattacharya, C Takemoto, T P Yao, T J Hemesath, D E Fisher.   

Abstract

During melanocyte development, the cytokine Steel factor activates its receptor c-Kit, initiating a signal transduction cascade, which is vital for lineage determination via unknown downstream nuclear targets. c-Kit has recently been found to trigger mitogen-activated protein kinase-mediated phosphorylation of Microphthalmia (Mi), a lineage-restricted transcription factor, which, like Steel factor and c-Kit, is essential for melanocyte development. This cascade results in increased Mi-dependent transcriptional reporter activity. Here we examine the mechanism by which Mi is activated by this pathway. Phosphorylation does not significantly alter Mi's nuclear localization, DNA binding, or dimerization. However, the transcriptional coactivator p300/CBP selectively associates with mitogen-activated protein kinase-phosphorylated Mi, even under conditions in which non-MAPK phospho-Mi is more abundant. Moreover, p300/CBP coactivates Mi transcriptional activity in a manner dependent upon this phosphorylation. Mi thus joins CREB as a transcription factor whose signal-responsive phosphorylation regulates coactivator recruitment, in this case modulating lineage development in melanocytes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9660747     DOI: 10.1074/jbc.273.29.17983

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi.

Authors:  M Wu; T J Hemesath; C M Takemoto; M A Horstmann; A G Wells; E R Price; D Z Fisher; D E Fisher
Journal:  Genes Dev       Date:  2000-02-01       Impact factor: 11.361

Review 2.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

3.  KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation.

Authors:  Youl-Nam Lee; Stephanie Brandal; Pierre Noel; Erik Wentzel; Joshua T Mendell; Michael A McDevitt; Reuben Kapur; Melody Carter; Dean D Metcalfe; Clifford M Takemoto
Journal:  Blood       Date:  2011-01-27       Impact factor: 22.113

Review 4.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

5.  Involvement of MITF-A, an alternative isoform of mi transcription factor, on the expression of tryptase gene in human mast cells.

Authors:  Sun-Hee Lee; Jeong-Heon Lee; Jeong-Heon Lee; Dae-Ki Kim
Journal:  Exp Mol Med       Date:  2010-05-31       Impact factor: 8.718

6.  MITF and cell proliferation: the role of alternative splice forms.

Authors:  Keren Bismuth; Dragan Maric; Heinz Arnheiter
Journal:  Pigment Cell Res       Date:  2005-10

7.  Sumoylation modulates transcriptional activity of MITF in a promoter-specific manner.

Authors:  Hideki Murakami; Heinz Arnheiter
Journal:  Pigment Cell Res       Date:  2005-08

Review 8.  The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology.

Authors:  Akinori Kawakami; David E Fisher
Journal:  Lab Invest       Date:  2017-03-06       Impact factor: 5.662

9.  Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment.

Authors:  Charles E Foulds; Mary L Nelson; Adam G Blaszczak; Barbara J Graves
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

10.  Role of BMP-4 and Its Signaling Pathways in Cultured Human Melanocytes.

Authors:  Hee-Young Park; Christina Wu; Mina Yaar; Christina M Stachur; Marita Kosmadaki; Barbara A Gilchrest
Journal:  Int J Cell Biol       Date:  2009-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.